Eton Pharmaceuticals Inc (NAS:ETON)

Q3 2024 Eton Pharmaceuticals Inc Earnings Call Transcript

Nov 12, 2024 / 09:30 PM GMT

Release Date Price: $9.17 (-5.56%)

Transcript 10-Q8-K

Key Points

Positve

Eton Pharmaceuticals Inc (ETON) achieved a record quarter of product sales with a 40% year-over-year increase, driven by strong performance in Alkindi Sprinkle and carglumic acid.
The company reached positive GAAP net income one quarter ahead of schedule, marking a significant profitability milestone.
Eton Pharmaceuticals Inc (ETON) announced the acquisition of Increlex, a transformational opportunity that aligns with their pediatric endocrinology focus.
The FDA accepted the new drug application for ET-400, with a PDUFA date set for February 28, 2025, indicating progress in their pipeline.
The company plans to expand and realign its sales force to maximize revenue potential, focusing on rare disease specialists and metabolic portfolio.

Negative

Despite growth, Alkindi Sprinkle faces a higher discontinuation rate than desired, which could impact long-term growth potential.
General and administrative expenses increased to $5.3 million from $4.3 million in the prior year, due to higher sales, marketing, and legal expenses.
The acquisition of Increlex will require significant investment in market education and infrastructure, potentially increasing SG&A expenses.
Carglumic Acid, while contributing to revenue growth, has limited future growth potential due to market saturation.
The company faces risks and uncertainties related to forward-looking statements, which could impact actual results.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ETON.OQ - Eton Pharmaceuticals Inc
Q3 2024 Eton Pharmaceuticals Inc Earnings Call
Nov 12, 2024 / 09:30PM GMT

=====================
Conference Call Participants
=====================
* David Krempa
* Sean Brynjelsen
* James Gruber
* Chase Knickerbocker

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------
Good afternoon, and welcome to the Eton Pharmaceuticals third-quarter 2024 financial results conference call. (Operator Instructions)

Please be advised that this call is being recorded at the company's request.

At this time, I would like to turn it over to David Krempa, Chief Business Officer at Eton Pharmaceuticals. Please proceed.

--------------------------------------------------------------------------------
David Krempa, [2]
----------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.